What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “RT001 is encapsulated di-deutero synthetic homologue of linoleic acid ethyl ester. Each capsule contains 960 mg of RT001.”In the company’s words, NCT03570931 on ClinicalTrials.gov
- Tested for
- Infantile Neuroaxonal Dystrophy
- Main trialPhase 2/3
- “The purpose of this study is to evaluate the efficacy and safety of RT001 in patients with Infantile Neuroaxonal Dystrophy (INAD).”In the company’s words, NCT03570931 on ClinicalTrials.gov
- Other names
- di-deuterated linoleic acid ester · Deuterated linoleic acid
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2/3Active, not recruiting | 9 Aug 2020 | A Study to Assess Efficacy and Safety of RT001 in Subjects With Infantile Neuroaxonal Dystrophy | |
| Phase 3Completed | 23 Aug 2021 | A Study to Assess Efficacy, Long Term Safety and Tolerability of RT001 in Subjects With Friedreich's Ataxia | |
| Phase 2Completed | 28 Jun 2022 | RT001 in Amyotrophic Lateral Sclerosis | |
| Phase 2Unknown | 30 Jul 2022 | RT001 in Patients With Progressive Supranuclear Palsy (PSP) PROGRESSIVE SUPRANUCLEAR PALSY |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026